Literature DB >> 12745416

Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine detoxification treatments.

Tracy Beswick1, David Best, Sian Rees, Jenny Bearn, Michael Gossop, John Strang.   

Abstract

Sleep disturbance experienced during methadone or lofexidine opiate detoxification was investigated in 118 opiate-dependent patients receiving inpatient detoxification treatment. Sleep was assessed at four time-points during opiate detoxification using a self-report questionnaire. Maximum sleep disruption occurred at completion of detoxification and during the protracted withdrawal period, with patients in the methadone group reporting higher levels of withdrawal symptoms, lower overall sleep, longer sleep latencies and significantly longer periods of time awake than lofexidine patients. Regression analyses demonstrated a significant relationship between sleep disturbance, protracted withdrawal and retention in treatment, in addition to the major treatment benefit of reduced sleep disturbance conferred by lofexidine treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745416     DOI: 10.1080/1355621031000069882

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  21 in total

1.  Evidence-based addiction medicine: the use of lofexidine for opioid detoxification.

Authors:  Babatunde Adetunji; Maju Mathews; Adedapo Williams; Olusanya Rufai
Journal:  Psychiatry (Edgmont)       Date:  2004-11

2.  Response inhibition and psychomotor speed during methadone maintenance: impact of treatment duration, dose, and sleep deprivation.

Authors:  B K Bracken; G H Trksak; D M Penetar; W L Tartarini; M A Maywalt; C M Dorsey; S E Lukas
Journal:  Drug Alcohol Depend       Date:  2012-04-30       Impact factor: 4.492

Review 3.  Addiction: the clinical interface.

Authors:  D Nutt; A Lingford-Hughes
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

4.  Prevalence of restless legs syndrome during detoxification from alcohol and opioids.

Authors:  Susan E Mackie; R Kathryn McHugh; Katherine McDermott; Margaret L Griffin; John W Winkelman; Roger D Weiss
Journal:  J Subst Abuse Treat       Date:  2016-10-06

5.  Affective and neuroendocrine effects of withdrawal from chronic, long-acting opiate administration.

Authors:  Kathryn L Hamilton; Andrew C Harris; Jonathan C Gewirtz
Journal:  Brain Res       Date:  2013-09-26       Impact factor: 3.252

6.  Opiate-induced changes in brain adenosine levels and narcotic drug responses.

Authors:  M Wu; P Sahbaie; M Zheng; R Lobato; D Boison; J D Clark; G Peltz
Journal:  Neuroscience       Date:  2012-10-22       Impact factor: 3.590

7.  Effects of sleep deprivation on sleep homeostasis and restoration during methadone-maintenance: a [31]P MRS brain imaging study.

Authors:  George H Trksak; J Eric Jensen; David T Plante; David M Penetar; Wendy L Tartarini; Melissa A Maywalt; Michael Brendel; Cynthia M Dorsey; Perry F Renshaw; Scott E Lukas
Journal:  Drug Alcohol Depend       Date:  2009-09-22       Impact factor: 4.492

8.  Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.

Authors:  Margaret Haney; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Stephanie Collins Reed; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2007-12-27       Impact factor: 4.530

Review 9.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

10.  Antagonist-precipitated and discontinuation-induced withdrawal in morphine-dependent rhesus monkeys.

Authors:  G L Becker; L R Gerak; W Koek; C P France
Journal:  Psychopharmacology (Berl)       Date:  2008-08-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.